Neuronetics, Inc. — Q1 2021 Form 10-Q Summary
Business context and reporting period
Neuronetics is a commercial-stage medical technology company that develops and markets the NeuroStar Advanced Therapy System, a non-invasive transcranial magnetic stimulation treatment cleared for adults with major depressive disorder. The filing covers the unaudited three months ended March 31, 2021, compared with the same period in 2020.
Revenue is generated primarily from NeuroStar system sales and recurring treatment sessions. The company operated as one business segment and had 147 employees at March 31, 2021.
Key financial metrics
| Metric | Q1 2021 | Q1 2020 | Change |
|---|---|---|---|
| Revenue | $12.3 million | $11.5 million | Up 7% |
| Gross profit | $10.1 million | $8.7 million | Up 16% |
| Gross margin | 81.9% | 75.5% | Up 6.4 percentage points |
| Operating loss | $6.9 million | $10.4 million | Improved $3.5 million |
| Net loss | $7.9 million | $12.6 million | Improved $4.7 million |
| Basic and diluted loss per share | $0.31 | $0.68 | Improved |
| Cash used in operating activities | $9.2 million | $13.7 million | Improved $4.5 million |
U.S. revenue was $11.8 million, or 96% of total revenue, while international revenue was $0.5 million, or 4%. U.S. treatment-session revenue increased 18% to $9.6 million, while U.S. system revenue decreased 32% to $1.8 million. The company sold 23 U.S. systems versus 38 in the prior-year quarter.
Sales and marketing expense decreased 20% to $8.6 million, primarily due to lower sales, reimbursement and clinical training costs. General and administrative expense increased 15% to $6.1 million, primarily due to higher personnel, bonus, salary and share-based compensation costs. Research and development expense decreased 24% to $2.3 million.
Share-based compensation expense was $2.2 million, compared with $1.2 million in Q1 2020. The increase was concentrated in general and administrative expense.
Balance sheet, debt and liquidity
- Cash and cash equivalents were $121.3 million at March 31, 2021, compared with $49.0 million at December 31, 2020.
- The increase in cash primarily reflected $80.6 million of net proceeds from a February 2021 public offering of 5.566 million common shares at $15.50 per share.
- Total assets were $152.3 million and stockholders’ equity was $102.0 million at March 31, 2021.
- Outstanding principal under the Solar credit facility was $35.0 million, with $34.8 million recorded net of debt discounts. The facility matures in February 2025.
- The facility carries a floating interest rate and has an interest-only period through March 2022, with a potential extension through March 2023 subject to covenant compliance.
- Management stated that cash and anticipated product revenue are expected to fund operations for at least 12 months from issuance of the financial statements.
Material changes versus the prior comparable period
- Revenue grew 7%, driven mainly by higher U.S. treatment-session volume and international system sales.
- Revenue mix shifted toward recurring treatment sessions and away from U.S. system sales, contributing to the gross-margin expansion to 81.9%.
- Operating expenses declined 11%, more than offsetting the increase in general and administrative costs.
- The prior-year period included a $0.9 million loss on extinguishment of debt; no comparable charge was recorded in Q1 2021.
- Operating cash burn improved but remained significant at $9.2 million.
- Common shares outstanding increased substantially following the February offering, from 19.1 million at December 31, 2020 to 25.8 million at March 31, 2021.
Guidance, outlook, risks and unusual items
The company did not provide specific financial guidance in the filing. Management expects continued operating losses for the next several years while investing in sales and marketing, international expansion, product development and additional indications, including potential bipolar depression and post-traumatic stress disorder applications.
COVID-19 continued to materially affect capital equipment sales, new patient treatment starts and system utilization. Customers continued to defer capital purchases, and management stated that the pandemic’s duration and financial impact remain difficult to predict.
Key risks include dependence on NeuroStar system sales and treatment utilization, third-party reimbursement and coverage, physician and patient demand, competition, product defects, supply-chain disruption, regulatory approvals, intellectual-property protection and the company’s history of losses. The Solar facility is secured by substantially all assets, including intellectual property, and contains financial covenants, events of default and subjective acceleration provisions.
The company was in compliance with all Solar facility covenants at March 31, 2021. It also reported no material legal proceedings, no material changes to previously disclosed risk factors and effective disclosure controls.
Severance charges were $0.2 million in Q1 2021, compared with $1.1 million in Q1 2020; $0.7 million remained accrued at March 31, 2021. After quarter-end, the company approved standardized executive severance provisions, including salary and benefits continuation, bonus provisions and potential accelerated equity vesting upon certain terminations or a change in control.
Investor verification points
- Verify whether treatment-session growth can offset continued weakness in system placements and COVID-19-related utilization pressure.
- Monitor cash burn relative to the $121.3 million cash balance and the company’s ability to reach profitability without additional financing.
- Review compliance with Solar facility revenue covenants and the timing of principal repayments beginning after the interest-only period.
- Assess dilution from the February 2021 equity offering, option exercises and outstanding equity awards.
- Evaluate reimbursement coverage, particularly in Japan and other international markets, and the concentration represented by one customer exceeding 10% of quarterly revenue.
- Track the impact of higher general and administrative and share-based compensation expenses on future operating leverage.